Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

January 17, 2020January 17, 2020

Case Report Describes Secondary Parkinsonism Due to Cavernoma in the Striatum

News

Secondary parkinsonism can be caused by a cavernoma — a cluster of abnormal blood vessels — located in a brain region involved in voluntary movement control, a case report ... Read more

January 15, 2020January 15, 2020

Biogen Acquires Pfizer’s PF-05251749, a Potential Disease-modifying Therapy for Parkinson’s, Alzheimer’s

News

Biogen is adding Pfizer’s PF-05251749 — a regulator of the body’s inner clock — to its group of potential disease-modifying therapies for Parkinson’s and Alzheimer’s diseases. Biogen plans to test ... Read more

January 7, 2020January 7, 2020

Cannabinoids Ease Motor Symptoms in Mouse Model of Parkinson’s, Early Results Show

News

Cannabinoid-based formulations in development at GB Sciences were able to ease behavioral symptoms linked to the loss of dopamine producing-nerve cells — a hallmark of Parkinson’s — in a ... Read more

January 3, 2020January 3, 2020

Patient Treatment Completed in Phase 1/2 Trial Testing Therapy Candidate CDNF in Parkinson’s Disease

News

Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for Parkinson’s disease, Herantis Pharma has announced. The trial (NCT03295786) is testing ... Read more

December 19, 2019December 19, 2019

Gosuranemab Fails to Show Efficacy in Phase 2 Progressive Supranuclear Palsy Trial

News

Gosuranemab failed to meet its primary and key secondary goals in a Phase 2 study evaluating its use in treating progressive supranuclear palsy, an atypical parkinsonian disorder, its developer, Biogen, ... Read more

December 18, 2019January 15, 2020

New Gene Therapy Delivery Method May Open BRAVE New World in Parkinson’s Research

News

A new method allows researchers to develop adeno-associated virus (AVV) — commonly used as the vehicle for gene therapies — that accurately target and deliver genes to specific cells ... Read more

December 12, 2019December 12, 2019

3D Structure of Brain Alpha-Synuclein More Heterogeneous Than Previously Thought, New Study Reports

News

Clumps, or aggregates of alpha-synuclein protein in the brain, a hallmark of Parkinon’s disease, are more heterogeneous than previously thought, according to a new study. Moreover, the protein’s 3D-structure ... Read more

December 11, 2019December 11, 2019

First DUB Enzymes Identified by Partnership as Potential Therapeutic Targets for Parkinson’s and Alzheimer’s

News

Mission Therapeutics and AbbVie have identified several molecules, called deubiquitylating enzymes, or DUBs, that may be potential therapeutic targets to treat Parkinson’s and Alzheimer’s diseases. This comes after the ... Read more

December 6, 2019December 6, 2019

Dosing Begins in Phase 2 Trial of CNM-Au8, Potential Therapy for Dopaminergic Neurons

News

A pilot Phase 2 study evaluating CNM-Au8, an investigational Parkinson’s treatment aiming to protect nerve cells, has started dosing patients, the therapy’s developer, Clene Nanomedicine, announced. The open-label REPAIR-PD (NCT03815916) clinical trial ... Read more

December 4, 2019December 4, 2019

RightEye’s Vision System for Early Diagnosis Named ‘Breakthrough Device’ by FDA

News

RightEye’s Vision System, an advanced eye-tracking device that measures eye tremors to help diagnose Parkinson’s disease at early stages, has been designated a breakthrough device by the U.S. Food and Drug Administration. ... Read more

Pin It on Pinterest